August 29, 2025 — Leads & Copy — Altamira Therapeutics Ltd. (OTCQB:CYTOF) reported its first half 2025 financial results and provided a business update, highlighting progress in its RNA delivery technology.
The company’s xPhore platform now works with circular RNA, branded as CycloPhore, expanding potential medical applications with enhanced protein expression and stability. Altamira has started evaluating CycloPhore technology with an undisclosed client and is progressing with plans for a partial spin-off of its RNA delivery business.
Altamira is pursuing a ‘picks and shovels’ strategy, licensing its xPhore platform for various RNA modalities. The company secured two new collaboration partners for evaluating RNA payloads delivered via xPhore nanoparticles. Altamira is also advancing the xPhore platform towards an IND filing and industrialization.
In non-core activities, Altamira is transitioning Bentrio to a Class IIa medical device in the EU and filing for clearance in Mainland China. The company expanded its intellectual property portfolio for AM-125, a treatment for acute vestibular syndrome, with patent coverage in over 50 countries.
In the first half of 2025, Altamira’s operating loss was $2.6 million, a 32.9% decrease from $3.9 million in 2024, driven by lower expenses. Net loss decreased by 64.6% to $1.5 million. The company expects operating expenses to decrease significantly after the partial spin-off of its ATAG subsidiary.
Altamira’s Senior Management will host an investor call today, Friday, August 29, at 08.00 a.m. ET to present a business update and first half 2025 results. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Investor Contact:
Hear@altamiratherapeutics.com
Source: Altamira Therapeutics
